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The efficacy of cytological screening in preventing adenocarcinoma of cervix uteri as compared to squamous cell cancer has been
evaluated by means of a case–control study in the province of Florence. The odds ratios of women who had a Pap test within the 3
years before the index date was 0.65 (95% confidence interval (CI) 0.26–1.64) and 0.15 (95% CI 0.07–0.31), for adenocarcinoma
and squamous cancer, respectively. The duration of the protective effect was shorter in women below the age of 40 years than in
older women.
British Journal of Cancer (2004) 90, 1784–1786. doi:10.1038/sj.bjc.6601754 www.bjcancer.com
Published online 30 March 2004
& 2004 Cancer Research UK
Keywords: case–control; cervical screening; cervical cancer; cervical adenocarcinoma
                                
Although the efficacy of cytological screening for cervical cancer is
beyond doubt (mortality and incidence have been falling
dramatically in Western Europe since screening has been adopted
on a large scale), the optimal resolution of several aspects of
cervical screening (e.g. compliance, criteria for referral, cost-
effectiveness) is still awaited. Recently, two problematic aspects
concerning Pap smear efficacy have been highlighted:
(1) Incidence rates of cervical adenocarcinomas are increasing
despite extensive screening (the reverse is true for squamous
carcinoma) (Smith et al, 2000), and cytological screening
seems to be less effective for adenocarcinoma than for
squamous carcinoma.
(2) Screening efficacy seems to be age dependent, and a shorter
rescreening interval has been suggested for younger women
(Sasieni et al, 2003).
The present case–control study aimed to evaluate the efficacy of
cytological screening in preventing adenocarcinoma of the cervix
as compared to squamous carcinoma, and in preventing cervical
cancer in younger (o40 years) as compared to older (X40 years)
women.
MATERIALS AND METHODS
The Centro per lo Studio e la Prevenzione Oncologica (CSPO) has
been running organised population-based cervical screening in the
Florence District since 1980. Screening details have been described
previously (Palli et al, 1990). A computerised archive collects Pap
smears that are read as well as the results obtained in screen
positive subjects referred and attending diagnostic assessment at
CSPO. Using several data sources, we estimated that about two-
third of all Pap smears (in a public or in a private setting)
performed in the screening area are archived in our centre.
Information on high-grade cervical intraepithelial neoplasias and
cervical cancers incident in screened subjects is obtained from a
population-based registry (Tuscany Tumour Registry: RTT),
incidence data available up to December 1999.
Cases
All women aged below 70 years registered at RTT as having a
cervical cancer diagnosed between 1994 and 1999 were considered.
Microinvasive carcinomas were excluded as well as nine cases in
women who had been resident in the screening area for less than 5
years. All records were reviewed to assess histological type
(squamous, adenocarcinoma, other, not specified). The date of
diagnosis (as reported in the RTT) was used as the index date of
the matched set in the case–control study.
Controls
Four controls for each case were randomly selected from the
municipality residence database among women matched by age
(same year of birth), who were alive at the index date of the
matched case. Women were eligible as controls if they had been
resident in the screening area for at least 5 years and if no
hysterectomy was known before the index date. Information on
hysterectomy was obtained from a database available in the
screening programme, which includes women reporting hyster-
ectomy when referring for Pap test and, more recently, those
recorded in local hospital records provided by the Tuscany Region.
This archive may be incomplete, but lack of information on
hysterectomy would conservatively affect the evaluation of
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a Pap test).
Screening history
All Pap tests archived in the screening database were considered
(positive or negative). In order to exclude smears taken because of
symptoms, smears taken within 12 months before the index date of
matched cases were ignored (for both cases and controls). Four
categories were defined for screening history analysis: (a) at least
one Pap test within 3 years before the index date; (b) most recent
Pap test more than 3 years, but less than 6 years before the index
date; (c) most recent Pap test more than 6 years before the index
data; and (d) no Pap test recorded in the database.
Statistical analysis
Using conditional logistic analysis in the STATA software, we
estimated the odds ratios (OR) of developing invasive cancer
associated with screening history. Separate analysis was under-
taken for squamous cancer and adenocarcinomas, as well as for
younger (o40 years) and older woman (X40 years). Covariates
introduced in the models were place of birth (Italy/outside) and
civil status (ever married vs never married), both variables being
available in the municipality residence database.
RESULTS
A total of 208 cases and 832 matched controls were selected.
Among cases, 148 (71.1%) had squamous carcinoma, 53 (25.5%)
adenocarcinoma and seven (3.4%) other or unspecified types. Ever
married women were slightly more frequent among controls than
among cases (88.6 vs 86.1%, P¼0.315), whereas women born
outside Italy were less frequent among controls as compared to
cases (0.7 vs 3.4%, P¼0.002).
Table 1 shows the distribution by age group of cases (overall and
according to histological type) and controls. Adenocarcinomas
occurred more frequently in younger women as compared to
squamous cancers (P¼0.045). In the same table are reported OR
(and 95% Confidence Interval – 95% CI) for squamous carcinoma
(relative to controls) associated with having been screened in the
previous 5 years. A marked increase is evident in the level of
protection for women older than 40 years.
Table 2 shows the screening history of cases (according to
histological type) and controls and the risk of developing a fully
invasive cervical cancer (squamous or adenocarcinoma) as a
function of time since last test. Overall, no Pap smear was recorded
in 52.7% of squamous, 39.6% of adenocarcinomas and 28.5% of
controls (Po0.001). Odds ratios were adjusted for civil status and
place of birth. Women who had a Pap test within 3 years before the
index date had an OR¼0.24 (95% CI¼0.14–0.41) as compared to
never screened subjects. The corresponding value for squamous
cancer was 0.15 (95% CI¼0.07–0.31) and that for adenocarcino-
mas was much higher (OR¼0.65; 95% CI¼0.26–1.64), but not
statistically significant.
Table 3 presents the results of multivariate analysis of the risk of
developing a fully invasive cervical cancer (squamous or
adenocarcinoma) as a function of time since the last test and of
age for two different strata of age (o40 vs X40 years). We
considered either a 3-year interval or a 5-year interval in order to
have more stable ORs. The ORs for invasive squamous cancer was
similar within 3 years before the index date (0.16 95% CI¼0.03–
0.77 or 0.15 95% CI¼0.07–0.33) for women o40 or X40 years,
respectively), whereas it was higher for younger women having the
last Pap test 43 years and o6 years before the index date (0.45
95% CI 0.14–1.48 for women aged o40 or 0.14 95% CI¼0.06–
0.33 for women aged X40, respectively).
DISCUSSION
Although case–control studies have been extensively used for
evaluating screening for cervical cancer, this approach has been
criticised on the grounds that a bias in favour of screening could
occur (Sasieni, 2001, pp 93–105; Zappa and Ciatto, 2001, pp 99–
118). In the present study, nevertheless, the main aim was not to
compare the protection in screened as compared to unscreened
Table 1 Distribution by age of cases (overall and according to histological type) and controls. Adjusted (for civil status and place of birth) OR of
developing a fully invasive squamous cancer (relative to controls) associated with having been screened in the previous 5 years
a
Age group
Histological type (%)
(years) Controls (%) Squamous (%) Adenocarcinomas (%) NOS and others (%) All cases (%) OR
b for squamous cancers (95%CI)
o40 207 (24.9) 30 (20.3) 20 (37.7) 2 (28.6) 52 (25.0) 0.32 (0.11–0.95)
40–49 250 (30.0) 50 (33.8) 11 (20.7) 1 (14.3) 62 (29.8) 0.11 (0.04–0.33)
50–59 163 (19.6) 28 (18.9) 11 (20.7) 2 (28.6) 41 (19.7) 0.08 (0.02–0.31)
60–69 212 (25.5) 40 (27.0) 11 (20.7) 2 (28.6) 53 (25.5) 0.22 (0.06–0.83)
All ages 832 (100) 148 (71.1) 53 (25.5) 7 (3.4) 208 (100) 0.17 (0.10–0.30)
aExcluding tests performed the year before the index date.
bBaseline: never screened (OR¼1.0). CI¼confidence interval; OR¼odds ratio; NOS¼not otherwise specified.
Table 2 Distribution of the cases (overall including not otherwise specified (NOS) and other cancers and divided by squamous cancer and
adenocarcinomas) and controls by history of screening. OR of developing a fully invasive cervical cancer by time since last test
a, adjusted for civil status and
birth place
Controls
Squamous Adenocarcinoma All cases
Time since last test
a No. (%) No. (%) OR (95% CI) No. (%) OR (95% CI) No. (%) OR (95% CI)
o3 years 187 (22.5) 11 (7.4) 0.15 (0.07–0.30) 9 (17.0) 0.65 (0.26–1.65) 22 (10.6) 0.25 (0.15–0.42)
3–o6 years 171 (20.5) 11 (7.4) 0.20 (0.10–0.39) 13 (24.5) 0.99 (0.43–2.29) 26 (12.5) 0.34 (0.21–0.56)
X6 years 237 (28.5) 48 (32.4) 0.56 (0.36–0.87) 10 (18.9) 0.54 (0.24–1.23) 59 (28.4) 0.56 (0.38–0.82)
Never screened 237 (28.5) 78 (52.7) 1.0
b 21 (39.6) 1.0
b 101 (48.6) 1.0
b
aExcluding tests performed the year before the index date.
bBaseline. OR¼odds ratios; CI¼confidence interval.
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effect of screening (a) for different histological type of cancer
(squamous and adenocarcinomas) or (b) in different age
groups, and we suppose that any potential bias should similarly
affect different compared strata. In other words, we cannot
exclude that our case–control approach may overestimate
the effect of screening, but we do not expect such an overestimate
to be different when comparing adenocarcinomas to squamous
cancers or younger to older women. However, other differential
biases are possible. If adenocarcinoma is more likely to be
screen detected, this would bias results in favour of a preventive
effect on adenocarcinoma (cases will have a full screening
interval, whereas controls will on average be halfway between
two screens); if high-risk young women are more likely to
attend whereas high-risk older women are more likely to refuse
screening, then such a difference could explain the result we have
observed.
The present study shows a lower protection from cytological
screening for adenocarcinoma than squamous carcinoma. The
result is consistent across age groups, and confirms the findings of
other case–control studies (Mitchell et al, 1995; Sato et al, 1997).
From a public health point of view, this might be of minor concern
as adenocarcinomas currently account for less than 25% of cervical
cancers, but such a lower protective effect of screening should be
kept in mind, considering that the incidence of adenocarcinoma is
increasing in younger women. The investigation of the possible
causes of a lower protective effect of cytological screening from
adenocarcinoma (e.g. lower sensitivity of cytology, different
sensitivity of smear sampling techniques, differences in sojourn
time intrinsic of adenocarcinoma) is essential to support further
action.
As far as the association of age with screening efficacy is
concerned, we found that the relative protection of screening from
invasive squamous carcinoma is shorter in younger (o40 years)
than in older (X40 years) women. This finding confirms the
results of a recent large study carried out in UK (Sasieni et al,
2003), which recommended a reduction from 5 to 3 years in the
rescreening interval for women below 50 years of age. In Italy, a 3-
year rescreening interval is recommended at any age, and such an
interval seems to grant sufficient protection. In the case of older
age groups, our findings suggest that a longer interval (5 years)
could be safely adopted.
The scenario of cervical cancer prevention is open to marked
changes, due to the widely recognised aetiological role of human
papilloma virus (HPV) and due to the possibility of the future use
of HPV vaccination as a radical alternative to screening; but the
role of HPV testing as a possible screening tool should not be
dismissed. Attempts to improve screening sensitivity and efficacy
in specific circumstances (younger age, adenocarcinoma) should
not be based only on a more aggressive cytological approach (e.g.
reduced rescreening interval, lower threshold for cytological
abnormality prompting diagnostic assessment) but also consider
the opportunity for adding HPV testing to Pap smear as a
screening tool.
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Table 3 OR of developing a fully invasive cervical cancer (overall including not otherwise specified (NOS) and other cancers and divided by squamous
cancer and adenocarcinomas) by time since last test
a and by age group (o40, 4¼40 years), adjusted for civil status and place of birth
Time since last test
a Squamous (95% CI) Adenocarcinoma (95% CI) All cases (95% CI)
o40 years
1–o3 years 0.16 (0.03–0.77) 0.76 (0.18–3.11) 0.35 (0.13–0.95)
3–o6 years 0.45 (0.14–1.48) 1.24 (0.26–5.86) 0.63 (0.26–1.52)
X6 years 0.68 (0.23–2.01) 1.03 (0.25–4.25) 0.83 (0.37–1.86)
1–o5 years 0.32 (0.11–0.95) 0.82 (0.24–2.79) 0.51 (0.23–1.11)
X5 years 0.51 (0.19–1.41) 1.25 (0.32–4.90) 0.71 (0.33–1.54)
Never screened 1.0
b 1.0
b 1.0
b
X40 years
1–o3 years 0.15 (0.07–0.33) 0.56 (0.16–2.01) 0.22 (0.12–0.42)
3–o6 years 0.14 (0.06–0.33) 0.78 (0.27–2.28) 0.26 (0.14–0.48)
X6 years 0.53 (0.32–0.88) 0.42 (0.14–1.24) 0.48 (0.31–0.74)
1–o5 years 0.14 (0.07–0.27) 0.67 (0.23–1.93) 0.24 (0.14–0.40)
X5 years 0.47 (0.29–0.77) 0.49 (0.18–1.30) 0.44 (0.29–0.68)
Never screened 1.0
b 1.0
b 1.0
b
aExcluding tests performed the year before the index date. OR¼odds ratios; CI¼confidence interval.
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